Jul 16, 2024, 14:12
Elisabetta Bonzano: Comparative biological activity of palbociclib and ribociclib in HR+ breast cancer
Elisabetta Bonzano, Associate Professor at MIUR, shared on X:
“Comparative biological activity of palbociclib and ribociclib in hormone receptor-positive breast cancer.
Both CDK4/6 inhibitors effectively modulate key biological pathways in HR+/HER2‑ breast cancer, nuances in their impact, particularly on the HER2‑enriched signature, are dose‑dependent, influenced by the addition of fulvestrant and warrant further investigation.”
Visit the article website.
Source: Elisabetta Bonzano/X
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Nov 20, 2024, 20:38
Nov 20, 2024, 20:27
Nov 20, 2024, 19:12
Nov 20, 2024, 19:12
Nov 20, 2024, 19:12
Nov 20, 2024, 19:12